Aptarro Releases 'AI Coding: Beyond the Hype' — New Report Reveals Why Automation Alone Won't Drive Revenue
TALLAHASSEE, Fla.--(BUSINESS WIRE)-- Aptarro today announced the release of its latest report, AI Coding: Beyond the Hype – A Straight-Talk Guide to AI Coding, offering healthcare leaders a clear-eyed view of why some early AI coding investments have failed to deliver on the big promise of moving the revenue needle—and how to build the right foundation for success.
Based on client insights and industry data, the report challenges the assumption that AI and automation are silver bullets. It highlights a growing gap between what AI coding alone can optimize—and what healthcare organizations need first: clean claims, compliant documentation, and faster, more reliable payments.
'AI coding can streamline workflows and reduce manual lift,' said Lori Jones, Chief Growth Officer at Aptarro. 'But without strong logic, rules, and visibility in place, it becomes a faster way to make the same mistakes. This guide is about showing leaders how to fix the foundation before scaling with AI alone.'
Key takeaways from the report:
Speed alone doesn't guarantee revenue. Organizations are learning that faster coding doesn't always mean faster payment.
AI coding is only as effective as the systems around it. Without payer rule logic, auditability, and consistent documentation, automation amplifies complexity instead of resolving it.
The winning model is a hybrid one—combining smart automation with the foundational tools and transparency teams need to actually get paid.
The report also includes a self-assessment checklist, helping organizations determine whether they need to clean up, speed up, or both before investing further in AI solutions.
AI coding helps save bottom line costs, but healthcare organizations need to also grow top line revenue.
The report is available for download here.
About Aptarro
At Aptarro, we help our customers make right easy by simplifying Revenue Cycle Management (RCM). Our solutions help healthcare providers reduce denials, increase accuracy, and improve staff productivity. Trusted by some of the largest healthcare networks in the U.S., Aptarro empowers organizations to navigate the complexities of healthcare billing with ease, allowing providers to focus on delivering quality care to their patients. Learn more at https://www.aptarro.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in Pulmonary Pharmacology and Therapeutics
REYKJAVIK, Iceland, June 11, 2025--(BUSINESS WIRE)--EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to inhaled pathogens, has had three articles published in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics. These publications describe the potential for EpiEndo's lead asset EP395, also known as 'glasmacinal', to be of therapeutic benefit in the treatment of COPD and support its continued clinical development. The article "Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial" reports that EP395 enhances the host defence response to inhaled LPS whilst reducing pro-inflammatory mediators. The paper was co-authored with investigators from Fraunhofer Institute for Toxicology and Experimental Medicine who conducted the study. The second article, "Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation" describes preclinical data that demonstrate EP395 has comparable inhibitory effects on acute neutrophilic airway inflammation to azithromycin, which is used chronically off-label for its immunomodulatory properties to reduce COPD exacerbations. Finally, "A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier" reports that EP395 has negligible antibiotic activity and enhances the barrier function of the respiratory epithelium. Maria Bech, CEO of EpiEndo Pharmaceticals commented: "It is great to see the publication of this clinical and pre-clinical research in a peer-reviewed journal, highlighting the efficacy we are seeing with glasmacinal in neutrophilic inflammation. "The anti-inflammatory effects of glasmacinal are comparable to those seen with azithromycin preclinically, but without anti-microbial activity. The clinical LPS study shows that EP395 enhances the host defence response to inhaled challenge, supporting our hypothesis that glasmacinal could be effective in reducing exacerbations in COPD but without developing anti-microbial resistance. "We continue to develop glasmacinal as a potential new oral treatment option for COPD patients, aiming to bring additional therapeutic options to patients with chronic respiratory diseases." Professor Clive Page, Emeritus Professor of Pharmacology, King's College London and Chairman of EpiEndo Pharmaceutical's Scientific Advisory Board added: "These exciting new data demonstrate glasmacinal's effect on neutrophilic inflammation both in a clinical study and in established non-clinical models of airways disease. These novel findings, coupled with data presented at ERS in 2024 on EP395's anti-inflammatory effect on eosinophilic inflammation (caused by allergens), demonstrate the broad anti-inflammatory activity of this drug that has the potential to provide a novel, groundbreaking approach to treat patients with COPD, irrespective of their type of inflammation." About EpiEndo Pharmaceuticals ( EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders. EpiEndo's new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as 'Barriolides™', show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo's lead asset, glasmacinal, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD). Glasmacinal aims to be a first on-market oral treatment which is anti-inflammatory and enhances the host defense response to inhaled pathogens such as viruses, bacteria & pollution. Therefore, glasmacinal has the potential to become an impactful treatment in reducing exacerbations in patients with COPD. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030. View source version on Contacts EpiEndo Pharmaceuticals: Maria Bech, CEO+354 454 0090 Vigo Consulting (media relations):Rozi Morris+44 20 7390 0230epiendo@ Sign in to access your portfolio
Business Wire
2 hours ago
- Business Wire
Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in
REYKJAVIK, Iceland--(BUSINESS WIRE)--EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to inhaled pathogens, has had three articles published in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics. These publications describe the potential for EpiEndo's lead asset EP395, also known as 'glasmacinal', to be of therapeutic benefit in the treatment of COPD and support its continued clinical development. The article 'Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial' reports that EP395 enhances the host defence response to inhaled LPS whilst reducing pro-inflammatory mediators. The paper was co-authored with investigators from Fraunhofer Institute for Toxicology and Experimental Medicine who conducted the study. The second article, 'Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation' describes preclinical data that demonstrate EP395 has comparable inhibitory effects on acute neutrophilic airway inflammation to azithromycin, which is used chronically off-label for its immunomodulatory properties to reduce COPD exacerbations. Finally, 'A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier ' reports that EP395 has negligible antibiotic activity and enhances the barrier function of the respiratory epithelium. Maria Bech, CEO of EpiEndo Pharmaceticals commented: 'It is great to see the publication of this clinical and pre-clinical research in a peer-reviewed journal, highlighting the efficacy we are seeing with glasmacinal in neutrophilic inflammation. 'The anti-inflammatory effects of glasmacinal are comparable to those seen with azithromycin preclinically, but without anti-microbial activity. The clinical LPS study shows that EP395 enhances the host defence response to inhaled challenge, supporting our hypothesis that glasmacinal could be effective in reducing exacerbations in COPD but without developing anti-microbial resistance. 'We continue to develop glasmacinal as a potential new oral treatment option for COPD patients, aiming to bring additional therapeutic options to patients with chronic respiratory diseases.' Professor Clive Page, Emeritus Professor of Pharmacology, King's College London and Chairman of EpiEndo Pharmaceutical's Scientific Advisory Board added: 'These exciting new data demonstrate glasmacinal's effect on neutrophilic inflammation both in a clinical study and in established non-clinical models of airways disease. These novel findings, coupled with data presented at ERS in 2024 on EP395's anti-inflammatory effect on eosinophilic inflammation (caused by allergens), demonstrate the broad anti-inflammatory activity of this drug that has the potential to provide a novel, groundbreaking approach to treat patients with COPD, irrespective of their type of inflammation.' About EpiEndo Pharmaceuticals ( EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders. EpiEndo's new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as 'Barriolides™', show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo's lead asset, glasmacinal, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD). Glasmacinal aims to be a first on-market oral treatment which is anti-inflammatory and enhances the host defense response to inhaled pathogens such as viruses, bacteria & pollution. Therefore, glasmacinal has the potential to become an impactful treatment in reducing exacerbations in patients with COPD. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030.
Business Wire
2 hours ago
- Business Wire
KBRA Releases Global ABS 2025: Day 1 Recap
LONDON--(BUSINESS WIRE)--The Global ABS 2025 conference, held in Barcelona on 10-12 June, opened to a record 5,000+ registered attendees, including over 2,000 issuers and investors, as well as a full programme. The conference celebrated its 29th anniversary as the largest annual European structured finance conference and is hosted by the Association for Financial Markets in Europe (AFME). This year marks the first time the event is being organised by FT Live, following its takeover of the previous organiser, Invisso. Judging by the strong attendance and KBRA's very active meeting calendar, the industry event reflects the growth momentum experienced by European securitisation markets. New transaction issuance started the year on a strong note and, despite a temporary pause, continued to build a robust and positive pipeline of transactions across all product types. Day 1 panels featured market updates on asset-backed securities (ABS), collateralised loan obligations (CLO), commercial mortgage-backed securities (CMBS), nonperforming loans (NPL), and more. Other discussions included broader topics such as regulation and synthetic risk transfer (SRT) securities, including several plenary sessions. KBRA speakers featured on a number of important panels covering solar panel loans, CLOs, and residential mortgage-backed securities (RMBS) markets. Click here to view a recap of some of the day's panel discussions. Recent Publications About KBRA KBRA, one of the major credit rating agencies, is registered in the U.S., EU, and the UK. KBRA is recognized as a Qualified Rating Agency in Taiwan, and is also a Designated Rating Organization for structured finance ratings in Canada. As a full-service credit rating agency, investors can use KBRA ratings for regulatory capital purposes in multiple jurisdictions. Doc ID: 1009819
